Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = new BL/BLICs

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
18 pages, 2476 KB  
Review
Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
by Andrea Marino, Edoardo Campanella, Stefano Stracquadanio, Maddalena Calvo, Giuseppe Migliorisi, Alice Nicolosi, Federica Cosentino, Stefano Marletta, Serena Spampinato, Pamela Prestifilippo, Stefania Stefani, Bruno Cacopardo and Giuseppe Nunnari
Antibiotics 2023, 12(10), 1521; https://doi.org/10.3390/antibiotics12101521 - 9 Oct 2023
Cited by 19 | Viewed by 9856
Abstract
This comprehensive review examines the unique attributes, distinctions, and clinical implications of ceftazidime–avibactam (CAZ-AVI) and meropenem–vaborbactam (MEM-VAB) against difficult-to-treat Enterobacterales infections. Our manuscript explores these antibiotics’ pharmacokinetic and pharmacodynamic properties, antimicrobial activities, in vitro susceptibility testing, and clinical data. Moreover, it includes a [...] Read more.
This comprehensive review examines the unique attributes, distinctions, and clinical implications of ceftazidime–avibactam (CAZ-AVI) and meropenem–vaborbactam (MEM-VAB) against difficult-to-treat Enterobacterales infections. Our manuscript explores these antibiotics’ pharmacokinetic and pharmacodynamic properties, antimicrobial activities, in vitro susceptibility testing, and clinical data. Moreover, it includes a meticulous examination of comparative clinical and microbiological studies, assessed and presented to provide clarity in making informed treatment choices for clinicians. Finally, we propose an expert opinion from a microbiological and a clinical point of view about their use in appropriate clinical settings. This is the first review aiming to provide healthcare professionals with valuable insights for making informed treatment decisions when combating carbapenem-resistant pathogens. Full article
Show Figures

Figure 1

Back to TopTop